Table 1. Patients demographics and baseline characteristics (n=82).
| Characteristics | Values | |
|---|---|---|
| Age (yr) | 56.0 (25–82) | |
| Sex | ||
| Male | 50 (61.0) | |
| Female | 32 (39.0) | |
| Histological subtypes | ||
| Well differentiated | 1 (1.2) | |
| Moderate differentiated | 12 (14.6) | |
| Poorly differentiated | 44 (53.7) | |
| Poorly cohesive carcinoma | 25 (30.5) | |
| Disease presentation | ||
| Synchronous | 51 (62.2) | |
| Metachronous | 31 (37.8) | |
| Palliative systemic chemotherapy | ||
| XELOX | 20 (24.4) | |
| FOLFOX | 19 (23.2) | |
| SP | 6 (7.3) | |
| FOLFIRI | 16 (19.5) | |
| Others* | 21 (25.6) | |
| Mean No. of systemic chemotherapy cycles | 9.1 (1–21) | |
| Mean No. of intraperitoneal chemotherapy cycles | 6.6 (1–41) | |
| Ascites grade | ||
| I (none) | 25 (30.5) | |
| II (minimal) | 26 (31.7) | |
| III (moderate) | 16 (19.5) | |
| IV (massive) | 15 (18.3) | |
Values are expressed as median (range) or number (%).
XELOX = capecitabine and oxaliplatin; FOLFOX = 5-fluorouracil, folinic acid, and oxaliplatin; SP = S-1 (tegafur/gimeracil/oteracil) and cisplatin; FOLFIRI = 5-fluorouracil, folinic acid, and irinotecan; DFP = docetaxel, 5-fluorouracil, and capecitabine; DCF = docetaxel, cisplatin, and 5-fluorouracil.
*Weekly paclitaxel, S-1 monotherapy, DFP, and DCF.